Compare peptides
Put two entries side by side — evidence, mechanism, risks, and community claims.
Mazdutide
Clinical
Research chemical
Summary
Investigational oxyntomodulin-analog dual agonist of GLP-1 and glucagon receptors under late-stage development for obesity and metabolic disease.
Categories
Metabolic & Body Comp
Mechanism
Balanced dual agonism at GLP-1R and GCGR with prolonged pharmacokinetics suitable for weekly SC dosing. Glucagon component may increase energy expenditure and improve liver fat metrics beyond pure GLP-1 agents.
Half-life
Designed for once-weekly dosing (investigational)
Routes
Subcutaneous injection
Legal / access
Investigational agent; not FDA-approved as of research catalog framing. Research peptides are not pharmaceutical mazdutide.
Key risks
- GI effects typical of incretins
- Heart-rate and metabolic effects from glucagon component
- Investigational safety profile evolving
Common claims
- Next-gen weight loss
- Liver fat / metabolic dual action
Select peptide B